Strategies to overcome the barrier: Use of nanoparticles as carriers and modulators of barrier properties

Cell and Tissue Research

Volumn 355, Issue 3, 2014, Pages 717-726

  Rempe, Ralf ^a   Cramer, Sandra ^a   Qiao, Ruirui ^b   Galla, Hans Joachim ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b INSTITUTE OF CHEMISTRY   (China)

Author keywords

Blood brain barrier; Endocytosis; Lactoferrin; Nanoparticles; Tight junction

Indexed keywords

NANOPARTICLE;

ANIMAL; BLOOD BRAIN BARRIER; DRUG EFFECTS; ENDOCYTOSIS; HUMAN; METABOLISM; PHYSIOLOGY; TIGHT JUNCTION;

ANIMALS; BLOOD-BRAIN BARRIER; ENDOCYTOSIS; HUMANS; NANOPARTICLES; TIGHT JUNCTIONS;

EID: 84899430038     PISSN: 0302766X     EISSN: 14320878     Source Type: Journal    
DOI: 10.1007/s00441-014-1819-7     Document Type: Review

References (80)

1. Abbott NJ, Ronnback L, Hansson E (2006) Astrocyte-endothelial interactions at the blood-brain barrier. Nat Rev Neurosci 7:41-53
2. Alam MI, Beg S, Samad A, Baboota S, Kohli K, Ali J, Ahuja A, Akbar M (2010) Strategy for effective brain drug delivery. Eur J Pharm Sci 40:385-403
3. Alyautdin RN, Petrov VE, Langer K, Berthold A, Kharkevich DA, Kreuter J (1997) Delivery of loperamide across the blood-brain barrier with polysorbate 80-coated polybutylcyanoacrylate nanoparticles. Pharm Res 14:325-328
4. Ambruosi A, Gelperina S, Khalansky A, Tanski S, Theisen A, Kreuter J (2006) Influence of surfactants, polymer and doxorubicin loading on the anti-tumour effect of poly(butyl cyanoacrylate) nanoparticles in a rat glioma model. J Microencapsul 23:582-592
5. Andrieux K, Couvreur P (2009) Polyalkylcyanoacrylate nanoparticles for delivery of drugs across the blood-brain barrier. Wiley Interdiscip Rev Nanomedicine Nanobiotechnol 1:463-474
6. Beduneau A, Saulnier P, Benoit J-P (2007) Active targeting of brain tumors using nanocarriers. Biomaterials 28:4947-4967
7. Begley DJ (2004) Delivery of therapeutic agents to the central nervous system: the problems and the possibilities. Pharmacol Ther 104:29-45
8. Bootz A, Russ T, Gores F, Karas M, Kreuter J (2005) Molecular weights of poly(butyl cyanoacrylate) nanoparticles determined by mass spectrometry and size exclusion chromatography. Eur J Pharm Biopharm 60:391-399
9. Brun E, Carrière M, Mabondzo A (2012) In vitro evidence of dysregulation of blood-brain barrier function after acute and repeated/long-term exposure to TiO2 nanoparticles. Biomaterials 33:886-896
10. Chen L, Yokel RA, Henning B, Toborek M (2008) Manufactured aluminium oxide nanoparticles decrease expression of tight junction proteins in brain vasculature. J Neuroimmune Pharmacol 3:286-295
11. Chrai SS, Murani R, Ahmad I (2001) Liposomes: a review, part one: manufacturing issues. BioPharm Int Appl Techn Biopharm Dev 14:10-14
12. Cornford EM, Young D, Paxton JW, Finlay GJ, Wilson WR, Pardridge WM (1992) Melphalan penetration of the blood-brain barrier via the neutral amino acid transporter in tumor-bearing brain. Cancer Res 52:138-143
13. Cramer S, Rempe R, Galla HJ (2012) Exploiting the properties of biomolecules for brain targeting of nanoparticulate systems. Curr Med Chem 19:3163-3187
14. Doherty GJ, McMahon HT (2009) Mechanisms of endocytosis. Ann Rev Biochem 78:857-902
15. Dohgu S, Banks WA (2008) Lipopolysaccharide-enhanced transcellular transport of HIV-1 across the blood-brain barrier is mediated by the p38 mitogen-activated protein kinase pathway. Exp Neurol 210:740-749
16. Eavarone DA, Yu X, Bellamkonda RV (2000) Targeted drug delivery to C6 glioma by transferrin-coupled liposomes. J Biomed Mater Res 51:10-14
17. Eisenblatter T, Galla HJ (2002) A new multidrug resistance protein at the blood-brain barrier. Biochem Biophys Res Commun 293:1273-1278
18. Garcia-Garcia E, Gil S, Andrieux K, Desmaele D, Nicolas V, Taran F, Georgin D, Andreux JP, Roux F, Couvreur P (2005) A relevant in vitro rat model for the evaluation of blood-brain barrier translocation of nanoparticles. Cell Mol Life Sci 62:1400-1408
19. Gessner A, Olbrich C, Schroder W, Kayser O, Muller RH (2001) The role of plasma proteins in brain targeting: species dependent protein adsorption patterns on brain-specific lipid drug conjugate (LDC) nanoparticles. Int J Pharm 214:87-91
20. Gil ES, Wu L, Xu L, Lowe TL (2012) β-Cyclodextrin-poly(β-Amino Ester) nanoparticles for sustained drug delivery across the blood-brain barrier. Biomacromolecules 13:3533-3541
21. Gojova A, Guo B, Kota RS, Rutledge JC, Kennedy IM, Barakat AI (2007) Induction of inflammation in vascular endothelial cells by metal oxide nanoparticles: effect of particle composition. Environ Health Perspect 115:403-409
22. Hall WA (1991) Transferrin receptor on glioblastoma multiforme. J Neurosurg 74:313-314
23. Halmos T, Santarromana M, Antonakis K, Scherman D (1996) Synthesis of glucose-chlorambucil derivatives and their recognition by the human GLUT1 glucose transporter. Eur J Pharmacol 318:477-484
24. Hu K, Li J, Shen Y, Lu W, Gao X, Zhang Q, Jiang X (2009) Lactoferrin-conjugated PEG-PLA nanoparticles with improved brain delivery: in vitro and in vivo evaluations. J Control Release 134:55-61
25. Huang RQ, Ke WL, Qu YH, Zhu JH, Pei YY, Jiang C (2007) Characterization of lactoferrin receptor in brain endothelial capillary cells and mouse brain. J Biomed Sci 14:121-128
26. Huynh NT, Passirani C, Saulnier P, Benoit JP (2009) Lipid nanocapsules: a new platform for nanomedicine. Int J Pharm 379:201-209
27. Ivanov AI (2008) Exocytosis and endocytosis. Humana, Totowa
28. Jefferies WA, Brandon MR, Hunt SV, Williams AF, Gatter KC, Mason DY (1984) Transferrin receptor on endothelium of brain capillaries. Nature 312:162-163
29. Jenning V, Thünemann AF, Gohla SH (2000) Characterisation of a novel solid lipid nanoparticle carrier system based on binary mixtures of liquid and solid lipids. Int J Pharm 199:167-177
30. Jia Q, Zeng J, Qiao R, Jing L, Peng L, Gu F, Gao M (2011) Gelification: an effective measure for achieving differently sized biocompatible Fe3O4 nanocrystals through a single preparation recipe. J Am Chem Soc 133:19512-19523
31. Juliano RL, Ling V (1976) A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 455:152-162
32. Kennedy IM, Wilson D, Barakat AI (2009) Uptake and inflammatory effects of nanoparticles in a human vascular endothelial cell line. Res Rep Health Eff Inst 3-32
33. Kratzer I, Wernig K, Panzenboeck U, Bernhart E, Reicher H, Wronski R, Windisch M, Hammer A, Malle E, Zimmer A, Sattler W (2007) Apolipoprotein A-I coating of protamine-oligonucleotide nanoparticles increases particle uptake and transcytosis in an in vitro model of the blood-brain barrier. J Control Release 117:301-311
34. Kreuter J, Shamenkov D, Petrov V, Ramge P, Cychutek K, Koch-Brandt C, Alyautdin R (2002) Apolipoprotein-mediated transport of nanoparticle-bound drugs across the blood-brain barrier. J Drug Target 10:317-325
35. Kreuter J, Ramge P, Petrov V, Hamm S, Gelperina SE, Engelhardt B, Alyautdin R, von Briesen H, Begley DJ (2003) Direct evidence that polysorbate-80-coated poly(butylcyanoacrylate) nanoparticles deliver drugs to the CNS via specific mechanisms requiring prior binding of drug to the nanoparticles. Pharm Res 20:409-416
36. Kreuter J, Hekmatara T, Dreis S, Vogel T, Gelperina S, Langer K (2007) Covalent attachment of apolipoprotein A-I and apolipoprotein B-100 to albumin nanoparticles enables drug transport into the brain. J Control Release 118:54-58
37. Kumagai AK, Eisenberg JB, Pardridge WM (1987) Absorptive-mediated endocytosis of cationized albumin and a beta-endorphin-cationized albumin chimeric peptide by isolated brain capillaries. Model system of blood-brain barrier transport. J Biol Chem 262:15214-15219
38. Laske DW, Youle RJ, Oldfield EH (1997) Tumor regression with regional distribution of the targeted toxin TF-CRM107 in patients with malignant brain tumors. Nat Med 3:1362-1368
39. Lemmen J, Tozakidis IEP, Galla H-J (2013) Pregnane X receptor upregulates ABC-transporter Abcg2 and Abcb1 at the blood-brain barrier. Brain Res 1491:1-13
40. Lenaerts V, Couvreur P, Christiaens-Leyh D, Joiris E, Roland M, Rollman B, Speiser P (1984) Degradation of poly (isobutyl cyanoacrylate) nanoparticles. Biomaterials 5:65-68
41. Levin VA (1980) Relationship of octanol/water partition coefficient and molecular weight to rat brain capillary permeability. J Med Chem 23:682-684
42. Liu L-b, Xue Y-x, Liu Y-h, Wang Y-b (2008) Bradykinin increases blood-tumor barrier permeability by down-regulating the expression levels of ZO-1, occludin, and claudin-5 and rearranging actin cytoskeleton. J Neurosci Res 86:1153-1168
43. Liu S, Jia B, Qiao R, Yang Z, Yu Z, Liu Z, Liu K, Shi J, Ouyang H, Wang F, Gao M (2009) A novel type of dual-modality molecular probe for MR and nuclear imaging of tumor: preparation, characterization and in vivo application. Mol Pharm 6:1074-1082
44. Lockman PR, Mumper RJ, Khan MA, Allen DD (2002) Nanoparticle technology for drug delivery across the blood-brain barrier. Drug Dev Ind Pharm 28:1-13
45. Lockman PR, Koziara J, Roder KE, Paulson J, Abbruscato TJ, Mumper RJ, Allen DD (2003) In vivo and in vitro assessment of baseline blood-brain barrier parameters in the presence of novel nanoparticles. Pharm Res 20:705-713
46. Lossinsky AS, Vorbrodt AW, Wisniewski HM (1995) Scanning and transmission electron microscopic studies of microvascular pathology in the osmotically impaired blood-brain barrier. J Neurocytol 24:795-806
47. Markoutsa E, Papadia K, Clemente C, Flores O, Antimisiaris SG (2012) Anti-Aβ-MAb and dually decorated nanoliposomes: effect of Aβ1-42 peptides on interaction with hCMEC/D3 cells. Eur J Pharm Biopharm 81:49-56
48. Marquet F, Tung Y-S, Teichert T, Ferrera VP, Konofagou EE (2011) Noninvasive, transient and selective blood-brain barrier opening in non-human primates in vivo. PLoS ONE 6:e22598
49. Martel CL, Mackic JB, Matsubara E, Governale S, Miguel C, Miao W, McComb JG, Frangione B, Ghiso J, Zlokovic BV (1997) Isoform-specific effects of apolipoproteins E2, E3, and E4 on cerebral capillary sequestration and blood-brain barrier transport of circulating Alzheimer's amyloid beta. J Neurochem 69:1995-2004
50. Michaelis K, Hoffmann MM, Dreis S, Herbert E, Alyautdin RN, Michaelis M, Kreuter J, Langer K (2006) Covalent linkage of apolipoprotein e to albumin nanoparticles strongly enhances drug transport into the brain. J Pharmacol Exp Ther 317:1246-1253
51. Miller DW, Keller BT, Borchardt RT (1994) Identification and distribution of insulin receptors on cultured bovine brain microvessel endothelial cells: possible function in insulin processing in the blood-brain barrier. J Cell Physiol 161:333-341
52. Mulik RS, Monkkonen J, Juvonen RO, Mahadik KR, Paradkar AR (2010) ApoE3 mediated poly(butyl) cyanoacrylate nanoparticles containing curcumin: study of enhanced activity of curcumin against beta amyloid induced cytotoxicity using in vitro cell culture model. Mol Pharm 7:815-825
53. Muller RH, Lherm C, Herbort J, Couvreur P (1990) In vitro model for the degradation of alkylcyanoacrylate nanoparticles. Biomaterials 11:590-595
54. Oerlemans C, Bult W, Bos M, Storm G, Nijsen J, Hennink W (2010) Polymeric micelles in anticancer therapy: targeting, imaging and triggered release. Pharm Res 27:2569-2589
55. Olivier J-C, Fenart L, Chauvet R, Pariat C, Cecchelli R, Couet W (1999) Indirect evidence that drug brain targeting using polysorbate 80-coated polybutylcyanoacrylate nanoparticles is related to toxicity. Pharm Res 16:1836-1842
56. Pang Z, Lu W, Gao H, Hu K, Chen J, Zhang C, Gao X, Jiang X, Zhu C (2008) Preparation and brain delivery property of biodegradable polymersomes conjugated with OX26. J Control Release 128:120-127
57. Patel M, Souto EB, Singh KK (2013) Advances in brain drug targeting and delivery: limitations and challenges of solid lipid nanoparticles. Expert Opin Drug Deliv 10:889-905
58. Petri B, Bootz A, Khalansky A, Hekmatara T, Muller R, Uhl R, Kreuter J, Gelperina S (2007) Chemotherapy of brain tumour using doxorubicin bound to surfactant-coated poly(butyl cyanoacrylate) nanoparticles: revisiting the role of surfactants. J Control Release 117:51-58
59. Provias J, Jeynes B (2011) Correlation analysis of capillary APOE, VEGF and eNOS expression in Alzheimer brains. Curr Alzheim Res 8:197-202
60. Qiao R, Jia Q, Hüwel S, Xia R, Liu T, Gao F, Galla H-J, Gao M (2012) Receptor-mediated delivery of magnetic nanoparticles across the blood-brain barrier. ACS Nano 6:3304-3310
61. Ramge P, Unger RE, Oltrogge JB, Zenker D, Begley D, Kreuter J, Von Briesen H (2000) Polysorbate-80 coating enhances uptake of polybutylcyanoacrylate (PBCA)-nanoparticles by human and bovine primary brain capillary endothelial cells. Eur J Neurosci 12:1931-1940
62. Rempe R (2012) Untersuchungen zum Transfer von Nanopartikeln über in vitro-Modelle der cerebralen Schrankensysteme. PhD thesis, University of Münster, Department of Biochemistry
63. Rempe R, Cramer S, Hüwel S, Galla H-J (2011) Transport of Poly(n-butylcyano-acrylate) nanoparticles across the blood-brain barrier in vitro and their influence on barrier integrity. Biochem Biophys Res Commun 406:64-69
64. Saupe A, Rades T (2006) Solid lipid nanoparticles. In: Mozafari MR (ed) Nanocarrier technologies. Springer, Netherlands, pp 41-50
65. Scherer D, Robinson JR, Kreuter J (1994) Influence of enzymes on the stability of polybutylcyanoacrylate nanoparticles. Int J Pharm 101:165-168
66. Sharma HS, Hussain S, Schlager J, Ali SF, Sharma A (2010) Influence of nanoparticles on blood-brain barrier permeability and brain edema formation in rats. Acta Neurochir Suppl 106:359-364
67. Talukder MJ, Takeuchi T, Harada E (2003) Receptor-mediated transport of lactoferrin into the cerebrospinal fluid via plasma in young calves. J Vet Med Sci 65:957-964
68. Trickler WJ, Lantz SM, Murdock RC, Schrand AM, Robinson BL, Newport GD, Schlager JJ, Oldenburg SJ, Paule MG, Slikker W Jr, Hussain SM, Ali SF (2010) Silver nanoparticle induced blood-brain barrier inflammation and increased permeability in primary rat brain microvessel endothelial cells. Toxicol Sci 118:160-170
69. Trickler WJ, Lantz SM, Murdock RC, Schrand AM, Robinson BL, Newport GD, Schlager JJ, Oldenburg SJ, Paule MG, Slikker W Jr, Hussain SM, Ali SF (2011) Brain microvessel endothelial cells responses to gold nanoparticles: In vitro pro-inflammatory mediators and permeability. Nanotoxicology 5:479-492
70. van de Waterbeemd H, Camenisch G, Folkers G, Chretien JR, Raevsky OA (1998) Estimation of blood-brain barrier crossing of drugs using molecular size and shape, and H-bonding descriptors. J Drug Target 6:151-165
71. Vauthier C, Dubernet C, Fattal E, Pinto-Alphandary H, Couvreur P (2003) Poly(alkylcyanoacrylates) as biodegradable materials for biomedical applications. Adv Drug Deliv Rev 55:519-548
72. Vezin WR, Florence AT (1980) In vitro heterogeneous degradation of poly(n-alkyl alpha-cyanoacrylates). J Biomed Mater Res 14:93-106
73. Wagner S, Kufleitner J, Zensi A, Dadparvar M, Wien S, Bungert J, Vogel T, Worek F, Kreuter J, von Briesen H (2010) Nanoparticulate transport of oximes over an in vitro blood-brain barrier model. PLoS ONE 5:e14213
74. Weigel PH, Oka JA (1981) Temperature dependence of endocytosis mediated by the asialoglycoprotein receptor in isolated rat hepatocytes. Evidence for two potentially rate-limiting steps. J Biol Chem 256:2615-2617
75. Williams DL, Dawson PA, Newman TC, Rudel LL (1985) Apolipoprotein E synthesis in peripheral tissues of nonhuman primates. J Biol Chem 260:2444-2451
76. Winkler K, Scharnagl H, Tisljar U, Hoschutzky H, Friedrich I, Hoffmann MM, Huttinger M, Wieland H, Marz W (1999) Competition of Abeta amyloid peptide and apolipoprotein E for receptor-mediated endocytosis. J Lipid Res 40:447-455
77. Witt KA, Gillespie TJ, Huber JD, Egleton RD, Davis TP (2001) Peptide drug modifications to enhance bioavailability and blood-brain barrier permeability. Peptides 22:2329-2343
78. Yang XX, Chen JH, Guo D (2005) Study of biocompatibility of polybutylcyanoacrylate nanoparticles. Di Yi Jun Yi Da Xue Xue Bao 25:1261-1263
79. Zensi A, Begley D, Pontikis C, Legros C, Mihoreanu L, Büchel C, Kreuter J (2010) Human serum albumin nanoparticles modified with apolipoprotein A-I cross the blood-brain barrier and enter the rodent brain. J Drug Target 18:842-848
80. Zhu MT, Wang B, Wang Y, Yuan L, Wang HJ, Wang M, Ouyang H, Chai ZF, Feng WY, Zhao YL (2011) Endothelial dysfunction and inflammation induced by iron oxide nanoparticle exposure: risk factors for early atherosclerosis. Toxicol Lett 203:162-171